A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma

Interventions

BIOLOGICAL: Sacituzumab tirumotecan
BIOLOGICAL: Enfortumab Vedotin
BIOLOGICAL: Pembrolizumab
DRUG: Supportive care measures

Sponsor

Merck Sharp & Dohme LLC